Material Issues

Main Initiatives and Results

Related SDGs

FY2023

FY2022

Number of approvals (Medium-TermManagement Plan 21-25, cumulative)

Scope of data

FY2021collection

29

24＊413(Global)

530(Global)

172027(Global)

222121(Global)

15116(Global)

Number of solutions provided to patients(Medium-Term Management Plan 21-25,cumulative)
Number of development pipelines
Awards received for drug discovery(total since 2007 merger)
Number of partnering projects
Creating new drugs, adding indications,①Innovativechanging dosage and administration,

pharmaceuticals andadding formulations, and providing aroundhealthcare services

the pill solutions(Medium-Term Management Plan 21-25,cumulative)
・654 packs(Therapeutic drugs for・299 packs

neuromyelitis optica

Medium-Term Management Plan 21-25
new product sales volume by year

(Therapeutic drugs forspectrum disorders)

neuromyelitis optica

・27,651 packs

spectrum disorders)(Therapeutic drugs for

・6,507 packs

tardive dyskinesia)(Therapeutic drugs for

・91,023 packs

tardive dyskinesia)（Therapeutic drugs for

・24,587 packs

123 packs（Therapeutic drugs forneuromyelitis optica(Global)spectrum disorders）

amyotrophic lateral sclerosis, （Therapeutic drugs fororal suspension)amyotrophic lateral sclerosis,・50,345 packs

oral suspension)(5 combined vaccine)②Quality assurance andstable supply

Building systems for the stable supply of

Number of product recalls (class I, II, and III)

reliable pharmaceuticals, and appropriate
responses to questions about quality

Customer satisfaction with questions aboutquality

class I0

class I0

class I

class Ⅱ2class Ⅱ1class Ⅱ 1class Ⅲ 0class Ⅲ 0class Ⅲ 0

91.2%

92.9%

92.4%

(Japan)1058477(Global)

Domestic：22,893

Domestic：20,200

Domestic：14,600

Overseas：42,393

Overseas：49,600

Overseas：54,100

282

219

167

(Global)20.46 million

24.25 million

31.44 million(Global)88＊49(Global)

44＊4

1(Global)3（Non-clinical）

3（Non-clinical）

2（Non-clinical）(Global)Vaccine: 11,335 doses

Vaccine: 9,281 doses

Vaccine: 34,633 doses(Global)

77%

77%79%(total favorable)*1(total favorable)*1(total favorable)*1

Overall satisfaction：5.00

Overall satisfaction：5.11

Overall satisfaction：5.05

Sympathy：5.09

Sympathy：5.12

Sympathy：5.09

Necessity：5.51

Necessity：5.62

Necessity：5.56

85%

84%

85%

(total favorable)*1(total favorable)*1(total favorable)*1

81%

79%

81%

(total favorable)*1(total favorable)*1(total favorable)*1

25.0%*5

10.0%

20.8%

(Global)

29.9% reduction*2

25.8% reduction*2

19.9% reduction*2(Global)

38.1% reduction*2

37.5% reduction*2

31.4% reduction*2(Global)

70.9% reduction*2

52.8% reduction*2

1.1% reduction*2(Japan)96%

95%(total favorable)*1(total favorable)*1*3

4.51 points(Global)Compliance: 5.09

Compliance: 5.15

Compliance: 5.14

Confidence：5.23

Confidence：5.31

Confidence：5.290(Japan)Number of external presentations on clinicalEstablishing a drug consultation center,③Appropriate use ofcollecting safety information, andproducts

providing information related to theappropriate use of products

research(papers/academic conferences, etc.)
Instances of safety information collected

Number of subsidized patient organizations(cumulative, total)
Number of health support website visitors
Supporting patients, developing④Access to healthcare

Number of pipelines for intractable and rare

therapeutic drugs for intractable and rare diseases
diseases, promoting project for infectious
Number of approvals for intractable and rarediseases that are prevalent in developing
diseasescountries(Medium-Term Management Plan 21-25)
Number and stage of infectious disease
treatment projects for developing countries
Number of health support programs indeveloping countries
Employee awareness survey results
Disseminating information and dialoging⑤Stakeholder engagementwith stakeholders including customers,
the general public, and employees(Sympathy/understanding of management
philosophy, rewarding/motivation)
Customer satisfaction survey results（7-point scale）
Employee survey results(Wellness item)⑥ Employee health, diversity
and inclusion

Promoting health management andimproving work environment where all
employees can play an active role

Employee survey results(Diversity and respect for individuals)
Diversity of management
GHG emissions

Reducing environmental impact in⑦Environment-friendly

corporate activities and educating

business

employees to raise environmental
awareness（vs. fiscal 2019）
Amount of water withdrawal（vs. fiscal 2019）
Amount of final waste disposed（vs. fiscal 2019）
Surveying employee awareness on

Working to cultivate an awareness of⑧Ethics, fairness andcompliance issues, establishing andintegrity

observing a variety of policies, andestablishing hotlines

compliance(Employee awareness survey / 5 points is aperfect score)
Customer satisfaction survey results(corporate image)（7-point scale）*1：Total favorable is the total score of the top two response choices (Agree/Tend to Agree).
*2: Due to the companies included in the calculation withdrawing from business and reorganizing their facilities, results from FY2019 onwards have also changed.
*3: In accordance with changes to survey methods, FY2022 results and the scope of the survey have also changed.
*4: FY2022 results were revised to account for some omissions and for revisions to aggregation methods.
*5: Due to a reorganization of overseas consolidated companies, the companies targeted for aggregation were revised.

(Global)(Global)(Japan)(Global)(Global)(Japan)